G J Nabel

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi The Gordon Wilson Lecture: viruses and human disease
    G J Nabel
    Vaccine Research Center, National Institutes of Health, 40 Convent Drive, MSC 3005, Bethesda, MD 20892, USA
    Trans Am Clin Climatol Assoc 112:79-84; discussion 86-8. 2001
  2. ncbi Progress in the rational design of an AIDS vaccine
    Gary J Nabel
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, MSC 3005, Bethesda, MD 20892, USA
    Philos Trans R Soc Lond B Biol Sci 366:2759-65. 2011
  3. ncbi Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Vaccine Immunol 19:1792-7. 2012
  4. ncbi Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo
    L M Akyurek
    Vascular Biology Branch, NHLBI National Institutes of Health, Bethesda, MD 20892, USA
    Mol Ther 3:779-86. 2001
  5. ncbi Vaccines for the prevention of HIV-1 disease
    J R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    Curr Opin Immunol 13:489-95. 2001
  6. ncbi Challenges and opportunities for development of an AIDS vaccine
    G J Nabel
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3005, USA
    Nature 410:1002-7. 2001
  7. ncbi Heme oxygenase-1 protects against vascular constriction and proliferation
    H J Duckers
    Vascular Biology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
    Nat Med 7:693-8. 2001
  8. ncbi Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression
    Y Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 75:4947-51. 2001
  9. ncbi A gene-based avian influenza vaccine in poultry
    S S Rao
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    Poult Sci 88:860-6. 2009
  10. ncbi A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, United States
    Vaccine 29:304-13. 2010

Collaborators

  • J R Mascola
  • B S Graham
  • Y Huang
  • J J Chen
  • N Desai
  • S S Rao
  • C A Andrews
  • M Roederer
  • J Goudsmit
  • Luis Bujanda
  • Peter D Kwong
  • Joseph Casazza
  • J E Ledgerwood
  • E G Nabel
  • M E Enama
  • G Yamshchikov
  • Z Hu
  • R Bailer
  • R A Koup
  • K Aoki
  • H J Duckers
  • Z Y Yang
  • N J Sullivan
  • M B Pearce
  • T M Tumpey
  • I J Gordon
  • L M Akyurek
  • H San
  • S Plummer
  • L Holman
  • Sarah Hubka
  • Cynthia Starr Hendel
  • Brenda Larkin
  • R A Sheets
  • S Mulangu
  • Kathy Rhone
  • Phyllis Zaia
  • Diane Johnson
  • Judith Starling
  • Ingelise Gordon
  • Rhonda Washington-Lewis
  • Hope Decederfelt
  • Sandra Sitar
  • M G Pau
  • Sara Jones
  • Laura Novik
  • LaChonne Stanford
  • Phillip Gomez
  • Trishna Goswami
  • P Costner
  • Raymond Cruz
  • J Petryniak
  • M E Lee
  • S Nallamshetty
  • M Kurooka
  • R Clinton Webb
  • S F Yet
  • J L Park
  • M Boehm
  • A L True
  • A Sanchez

Detail Information

Publications12

  1. ncbi The Gordon Wilson Lecture: viruses and human disease
    G J Nabel
    Vaccine Research Center, National Institutes of Health, 40 Convent Drive, MSC 3005, Bethesda, MD 20892, USA
    Trans Am Clin Climatol Assoc 112:79-84; discussion 86-8. 2001
    ..In this way, Ebola virus infection provides a useful paradigm for understanding the genetic determinants of viral disease and in facilitating the development of treatments and prevention of viral infections...
  2. ncbi Progress in the rational design of an AIDS vaccine
    Gary J Nabel
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, MSC 3005, Bethesda, MD 20892, USA
    Philos Trans R Soc Lond B Biol Sci 366:2759-65. 2011
    ....
  3. ncbi Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Vaccine Immunol 19:1792-7. 2012
    ..m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens...
  4. ncbi Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo
    L M Akyurek
    Vascular Biology Branch, NHLBI National Institutes of Health, Bethesda, MD 20892, USA
    Mol Ther 3:779-86. 2001
    ..These modifications in TKciteGK vectors and GCV showed enhanced efficacy at lower prodrug doses, leading to improved safety for cardiovascular gene therapy...
  5. ncbi Vaccines for the prevention of HIV-1 disease
    J R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    Curr Opin Immunol 13:489-95. 2001
    ....
  6. ncbi Challenges and opportunities for development of an AIDS vaccine
    G J Nabel
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3005, USA
    Nature 410:1002-7. 2001
    ....
  7. ncbi Heme oxygenase-1 protects against vascular constriction and proliferation
    H J Duckers
    Vascular Biology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
    Nat Med 7:693-8. 2001
    ..Induction of the HO-1 pathway moderates the severity of vascular injury by at least two adaptive mechanisms independent of nitric oxide, and is a potential therapeutic target for diseases of the vasculature...
  8. ncbi Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression
    Y Huang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 75:4947-51. 2001
    ..A Gag-Pol fusion protein stimulated cytotoxic T lymphocyte and antibody responses to Gag and Pol, while a Gag-Pol pseudoparticle did not elicit substantial Pol responses. This fusion protein may be useful for AIDS vaccines...
  9. ncbi A gene-based avian influenza vaccine in poultry
    S S Rao
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    Poult Sci 88:860-6. 2009
    ..Here we review the features of gene-based vaccination that may facilitate the control of HPAI H5N1 in poultry, and highlight the development of a hemagglutinin-based multivalent DNA vaccine that confers protection in mice and chickens...
  10. ncbi A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults
    J E Ledgerwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3017, United States
    Vaccine 29:304-13. 2010
    ..This recombinant Ebola virus vaccine was safe and subjects developed antigen specific humoral and cellular immune responses...
  11. ncbi Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity
    K Aoki
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    Nat Immunol 2:333-7. 2001
    ..The retention of soluble CD95L on extracellular matrices is likely to play an important role in the development of peripheral tolerance in immune-privileged sites...
  12. ncbi Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury
    Z Y Yang
    Vaccine Research Center, National Institutes of Health, 40 Convent Drive, Bethesda, Maryland 20892 3005, USA
    Nat Med 6:886-9. 2000
    ..These findings indicate that GP, through its mucin domain, is the viral determinant of Ebola pathogenicity and likely contributes to hemorrhage during infection...